WALTHAM, Mass., March 26, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide, which AMAG in-licensed from Palatin Technologies, Inc. in February 2017. Bremelanotide is a first-in-class melanocortin 4 receptor agonist developed to treat acquired,… More

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Cowen and Company 38th Annual Health Care ConferenceMonday, March 12, 2018 at 1:30 p.m. ET Location: Boston, MA Barclays Global Healthcare ConferenceWednesday, March 14, 2018 at 3:50 p.m. ETLocation: Miami, FL… More

2017 GAAP Revenue Increased 15% Year-over-Year February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2017. Total… More

WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 27, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and… More

Marks Second FDA Approval for AMAG this Month; Company to File NDA for Bremelanotide, A Novel Women’s Health Product, Later this Quarter WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) approved the Makena® subcutaneous auto-injector drug-device combination product as a ready-to-administer… More

Feraheme is Now a Treatment Option for All Eligible Adult Patients with Iron Deficiency Anemia WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the existing label for Feraheme® (ferumoxytol injection) beyond the current chronic kidney… More

WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provided a business update, including preliminary unaudited fourth quarter and full year 2017 financial results and 2018 financial guidance. The company will present further details at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2018 at… More

WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) —  As part of the company’s ongoing support of maternal and neonatal health, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has awarded four grants totaling $300,000 to independent researchers in the field. “While there are therapeutic options like Makena® (hydroxyprogesterone caproate injection), the only FDA-approved medicine indicated to… More

WALTHAM, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time), in San Francisco, California. To access the live webcast of… More

Patent designed to protect the subcutaneous administration of Makena(R) (hydroxyprogesterone caproate injection) WALTHAM, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the issuance of U.S. Patent Number 9,844,558 entitled “Methods of Reducing Risk of Preterm Birth.” This newly issued patent is directed to subcutaneous administration and dosing of Makena® (hydroxyprogesterone caproate injection)… More